Enveric Biosciences, Inc. today announced that it has entered into an agreement with Avance Clinical for its planned Phase 1 clinical trial of EB-373, the company’s lead candidate targeting the treatment of anxiety disorders.
Rodney Varner , CEO of Genprex, Inc. today commended The U.S. Food and Drug Administration’s (FDA) initiative that aims to expedite the development of gene therapies for patients with rare diseases.
Genprex CEO Commends FDA’s Initiative to Accelerate Approval Process for Gene Therapies Read More »
Xenetic Biosciences, Inc. today reported its financial results for the full year 2022 and provided a business update.
Vividion Therapeutics, Inc. today announced that Matt Patricelli, Ph.D. has been promoted to Chief Scientific Officer.
Vividion Therapeutics Promotes Matt Patricelli to Chief Scientific Officer Read More »
Pragma Bio developed a first-of-its-kind-map of chemicals designed by nature, housed in humans, and linked to immune-related health outcomes
Pionyr Immunotherapeutics, Inc., a company developing first-in-class Myeloid TuningTM antibody therapeutics that enhance the body’s anti-tumor immunity by altering, or “tuning,” immune cells within the tumor microenvironment, announced that Pionyr and Gilead Sciences, Inc. have mutually agreed to change their 2020 exclusive option agreements.
Pionyr Immunotherapeutics and Gilead Change Exclusive Option Agreement Read More »
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, announced that management will present at the Stifel 2023 CNS Days on Wednesday, March 29, 2023, at 8:00 a.m. ET.
Karuna Therapeutics to Present at the Stifel 2023 CNS Days Read More »
Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, announced an upcoming poster presentation for the ongoing Phase 1/2 ALKOVE-1 study of its ALK-selective inhibitor, NVL-655.
On 22 March 2023, the Board of Directors of Nordic Nanovector ASA approved the Company’s financial statements for 2022.
Nordic Nanovector – Annual and Remuneration Reports Approved Read More »
NovaBay® Pharmaceuticals, Inc. announces that it will report financial results for the three and 12 months ended December 31, 2022 after market close on Thursday, March 30, 2023 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time.
